Skip to main content
. 2011 Aug 19;301(5):H2147–H2153. doi: 10.1152/ajpheart.01216.2010

Fig. 3.

Fig. 3.

Effect of ouabain administration on MAP (A) or HR (B) recorded after the indicated treatments. Infusions (icv and/or sc) of ouabain (171 pmol/day) were carried out for a period of 8 days as described in materials and methods, and blood pressures and HRs were measured on the last day of treatment; n = 5 to 6 in each group, except for icv ouabain (n = 8). Values represent means ± SE. *P < 0.05 vs. icv aCSF group. **P < 0.05 vs. α2R/R-icv ouabain and WT-sc ouabain groups.